###begin article-title 0
###xml 12 27 <span type="species:ncbi:10090">transgenic mice</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 46 62 46 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#945;-synuclein </italic>
###xml 377 384 361 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 397 402 <span type="species:ncbi:10090">mouse</span>
###xml 463 468 <span type="species:ncbi:9606">human</span>
Missense mutations and multiplications of the alpha-synuclein gene cause autosomal dominant familial Parkinson's disease (PD). alpha-Synuclein protein is also a major component of Lewy bodies, the hallmark pathological inclusions of PD. Therefore, alpha-synuclein plays an important role in the pathogenesis of familial and sporadic PD. To model alpha-synuclein-linked disease in vivo, transgenic mouse models have been developed that express wild-type or mutant human alpha-synuclein from a variety of neuronal-selective heterologous promoter elements. These models exhibit a variety of behavioral and neuropathological features resembling some aspects of PD. However, an important deficiency of these models is the observed lack of robust or progressive nigrostriatal dopaminergic neuronal degeneration that is characteristic of PD.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 46 61 <span type="species:ncbi:10090">transgenic mice</span>
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 188 194 <span type="species:ncbi:10090">murine</span>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
We have developed conditional alpha-synuclein transgenic mice that can express A53T, E46K or C-terminally truncated (1-119) human alpha-synuclein pathological variants from the endogenous murine ROSA26 promoter in a Cre recombinase-dependent manner. Using these mice, we have evaluated the expression of these alpha-synuclein variants on the integrity and viability of nigral dopaminergic neurons with age. Expression of A53T alpha-synuclein or truncated alphaSyn119 selectively in nigrostriatal pathway dopaminergic neurons for up to 12 months fails to precipitate dopaminergic neuronal loss in these mice. However, alphaSyn119 expression in nigral dopaminergic neurons for up to 12 months causes a marked reduction in the levels of striatal dopamine and its metabolites together with other subtle neurochemical alterations.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 305 312 297 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 66 81 <span type="species:ncbi:10090">transgenic mice</span>
###xml 186 191 <span type="species:ncbi:10090">mouse</span>
###xml 351 356 <span type="species:ncbi:10090">mouse</span>
###xml 662 677 <span type="species:ncbi:10090">transgenic mice</span>
We have developed and evaluated novel conditional alpha-synuclein transgenic mice with transgene expression directed selectively to nigrostriatal dopaminergic neurons as a potential new mouse model of PD. Our data support the pathophysiological relevance of C-terminally truncated alpha-synuclein species in vivo. The expression of alphaSyn119 in the mouse nigrostriatal dopaminergic pathway may provide a useful model of striatal dopamine depletion and could potentially provide a presymptomatic model of PD perhaps representative of the earliest derangements in dopaminergic neuronal function observed prior to neuronal loss. These conditional alpha-synuclein transgenic mice provide novel tools for evaluating and dissecting the age-related effects of alpha-synuclein pathological variants on the function of the nigrostriatal dopaminergic pathway or other specific neuronal populations.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 673 674 669 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 958 959 950 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 960 961 952 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 101 109 <span type="species:ncbi:405018">cardinal</span>
Parkinson's disease (PD) is the most common neurodegenerative movement disorder characterized by the cardinal symptoms of muscular rigidity, resting tremor and bradykinesia [1,2]. Underlying these motor deficits is the progressive loss of dopaminergic neurons of the substantia nigra pars compacta in addition to several other neuronal populations, the corresponding reduction of striatal dopamine levels, and the appearance of Lewy bodies and Lewy neurites in surviving neurons of the brainstem [1-3]. Lewy bodies are round eosinophilic intracytoplasmic proteinaceous inclusions composed of filamentous material, a major component of which is the protein alpha-synuclein [4]. Missense mutations (A30P, E46K and A53T) and multiplications of the alpha-synuclein gene cause rare autosomal dominant familial forms of PD that often manifest disease in some families with an extended clinical and pathological spectrum resembling dementia with Lewy bodies (DLB) [5-9]. Thus, alpha-synuclein most likely plays a key role in the pathogenesis of familial and sporadic PD in addition to DLB.
###end p 9
###begin p 10
###xml 482 484 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 485 487 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 694 696 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 697 699 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 911 919 887 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
It is not clear how mutations in alpha-synuclein, or increased levels of the wild-type alpha-synuclein protein due to gene multiplications, precipitate the demise of nigral dopaminergic neurons in familial PD. How alpha-synuclein contributes to the pathogenesis of the more common sporadic form of PD is also not known. It has been postulated that post-translational modifications of normal alpha-synuclein, including oxidation, nitration, phosphorylation or C-terminal truncation [10-13], could contribute to alpha-synuclein dysfunction and neuropathology in sporadic PD. The appearance of some of these modifications correlates well with neuronal loss and/or pathology in sporadic PD brains [11-13]. Furthermore, the exact role of Lewy bodies in dopaminergic neuronal degeneration in PD remains enigmatic. Therefore, clarifying the mechanisms underlying alpha-synuclein-induced dopaminergic neurodegeneration in vivo is critical to understanding the pathogenesis of familial and sporadic PD.
###end p 10
###begin p 11
###xml 187 189 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 190 192 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 493 495 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 496 498 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 575 577 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 578 580 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1148 1150 1129 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1151 1153 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1154 1156 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1370 1372 1347 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1373 1375 1350 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
###xml 207 222 <span type="species:ncbi:10090">transgenic mice</span>
###xml 274 279 <span type="species:ncbi:9606">human</span>
###xml 403 408 <span type="species:ncbi:10090">mouse</span>
###xml 424 429 <span type="species:ncbi:10090">mouse</span>
###xml 440 445 <span type="species:ncbi:9606">human</span>
###xml 535 538 <span type="species:ncbi:10116">rat</span>
###xml 676 681 <span type="species:ncbi:10090">mouse</span>
###xml 984 989 <span type="species:ncbi:10090">mouse</span>
###xml 1199 1204 <span type="species:ncbi:10090">mouse</span>
###xml 1405 1410 <span type="species:ncbi:10090">mouse</span>
###xml 1675 1680 <span type="species:ncbi:10090">mouse</span>
###xml 2126 2131 <span type="species:ncbi:10090">mouse</span>
It is now clear from studies of transgenic mouse models that alpha-synuclein pathogenic mutations induce neuronal dysfunction and degeneration through a toxic gain-of-function mechanism [14-16]. A number of transgenic mice have been created that express wild-type or mutant human alpha-synuclein in neurons from an array of different heterologous promoter elements. These include the broadly expressing mouse prion protein, mouse Thy-1 and human platelet-derived growth factor-beta promoters [17-23], or the catecholaminergic-specific rat tyrosine hydroxylase (TH) promoter [24-27]. A wide range of alpha-synuclein-related neurological phenotypes have been described in these mouse models that resemble some features of PD, such as behavioral motor deficits, neuronal loss, reduced striatal dopamine levels, and the formation of filamentous and non-filamentous alpha-synuclein-positive inclusions or aggregates. Many of these phenotypes, however, are not usually observed in the same mouse model. The most severe phenotypes tend to be observed with expression of the A53T variant whereas the wild-type protein is only ever rarely toxic to neurons [15,17,19]. Despite the plethora of alpha-synuclein mouse models that have been created, only very few of these exhibit a loss of nigral dopaminergic neurons, and in general this neuronal loss is not progressive or robust [26,28]. Therefore, alpha-synuclein mouse models do not currently exist that reliably recapitulate essential features of PD especially the loss of nigral dopaminergic neurons, the neuropathological hallmark of the disease. Thus, there is a requirement for the development of new alpha-synuclein transgenic mouse models that can faithfully recapitulate the dysfunction of the nigrostriatal dopaminergic pathway in PD. Such models may arise through improvements in transgenic technology to increase transgene expression levels and dopaminergic neuronal specificity, as well as through the identification of more toxic alpha-synuclein pathogenic variants. A combination of these approaches could prove to be advantageous in developing faithful alpha-synuclein mouse models of PD.
###end p 11
###begin p 12
###xml 356 358 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 359 361 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 374 383 354 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 606 608 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 609 611 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 612 614 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 912 914 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 915 917 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 918 920 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1517 1519 1449 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1520 1522 1452 1454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 258 263 <span type="species:ncbi:9606">human</span>
###xml 293 308 <span type="species:ncbi:10090">transgenic mice</span>
###xml 408 413 <span type="species:ncbi:9606">human</span>
###xml 1364 1379 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1500 1503 <span type="species:ncbi:10116">rat</span>
###xml 1545 1549 <span type="species:ncbi:10090">mice</span>
Recent studies have highlighted the pathophysiological significance of C-terminally truncated alpha-synuclein species. Most recently, C-terminal truncation variants, including alphaSyn119, alphaSyn122 and alphaSyn123, have been detected in brain tissue from human PD cases and alpha-synuclein transgenic mice, and were found to be enriched in Lewy bodies [13,29]. Moreover, in vitro studies demonstrate that human alpha-synuclein lacking the C-terminal 20 or 30 amino acids (alphaSyn120 or alphaSyn130) assemble more readily into filaments resembling the alpha-synuclein filaments observed in Lewy bodies [13,29-31]. Disease-associated mutations in alpha-synuclein promote the accumulation of these truncated filaments compared to the wild-type protein, and C-terminally truncated species can enhance the aggregation of wild-type alpha-synuclein at low substoichiometric ratios suggestive of a seeding capacity [13,29,31]. Therefore, C-terminal truncations of alpha-synuclein could potentially advance disease progression or propagation through promoting the pathological aggregation and accumulation of alpha-synuclein. At this juncture, however, the role of C-terminally truncated alpha-synuclein species in the pathogenesis of PD is poorly understood. To further understand the pathophysiological significance of C-terminally truncated alpha-synuclein species, transgenic mice have recently been developed that express wild-type alphaSyn120 or A53T mutant alphaSyn130 truncation variants from the rat TH promoter [25,26]. Collectively, these mice exhibit filamentous and non-filamentous alpha-synuclein-positive aggregates, deficits in locomotion, reduced striatal dopamine levels, and in the A53T-alphaSyn130 model a developmental loss of TH-positive nigral neurons and striatal nerve terminals.
###end p 12
###begin p 13
###xml 415 417 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 507 510 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 938 940 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 941 943 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1018 1020 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 107 122 <span type="species:ncbi:10090">transgenic mice</span>
###xml 165 170 <span type="species:ncbi:9606">human</span>
###xml 343 358 <span type="species:ncbi:10090">transgenic mice</span>
###xml 459 474 <span type="species:ncbi:10090">transgenic mice</span>
###xml 596 601 <span type="species:ncbi:9606">human</span>
###xml 756 761 <span type="species:ncbi:10090">mouse</span>
Prior to the publication of these alpha-synuclein truncation models, we set out to develop a collection of transgenic mice capable of producing robust expression of human alpha-synuclein variants selectively in neurons of the nigrostriatal dopaminergic pathway. Encouraged by the promising neurodegenerative phenotype exhibited by conditional transgenic mice expressing a polyglutamine-expanded huntingtin protein [32], we chose to create similar conditional transgenic mice through gene targeting of a Cre-loxP-based transgene cassette at the ROSA26 genomic locus to express E46K or A53T mutant human alpha-synuclein, or the putative pathogenic C-terminal truncation, alphaSyn119, in a Cre recombinase-dependent manner. It is worth noting that transgenic mouse models expressing E46K alpha-synuclein do not currently exist, and that previous alpha-synuclein truncation models rely upon artificial truncations (alphaSyn120, alphaSyn130) [25,26] rather than truncations associated with disease pathology (alphaSyn119) [13]. Here, we combine conditional transgenic technology with new pathological variants of alpha-synuclein to evaluate the effects of expressing these alpha-synuclein variants directly in nigrostriatal pathway dopaminergic neurons.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
###xml 47 51 <span type="species:ncbi:10090">Mice</span>
###xml 56 61 <span type="species:ncbi:9606">Human</span>
Development of Cre-loxP Conditional Transgenic Mice for Human alpha-Synuclein Variants
###end title 15
###begin p 16
###xml 510 512 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 621 625 597 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP</italic>
###xml 761 763 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 764 766 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 986 988 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1120 1123 1088 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 1276 1278 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
###xml 90 105 <span type="species:ncbi:10090">transgenic mice</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 252 267 <span type="species:ncbi:10090">transgenic mice</span>
###xml 294 299 <span type="species:ncbi:9606">human</span>
###xml 396 402 <span type="species:ncbi:10090">murine</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 707 713 <span type="species:ncbi:10090">murine</span>
###xml 868 874 <span type="species:ncbi:10090">murine</span>
###xml 1049 1053 <span type="species:ncbi:10090">mice</span>
###xml 1337 1341 <span type="species:ncbi:10090">mice</span>
To develop new alpha-synuclein mouse models of PD, our strategy was to create conditional transgenic mice that selectively express pathological human alpha-synuclein variants in dopaminergic neurons of the nigrostriatal pathway. Therefore, conditional transgenic mice were created that express human A53T or E46K alpha-synuclein or C-terminally truncated alphaSyn119 variants from the endogenous murine ROSA26 promoter in a Cre recombinase-dependent manner; hereafter referred to as ROSA26-alphaSyn mice (Fig. 1A). In these models, a conditional cassette containing an alpha-synuclein transgene immediately preceded by a loxP-flanked transcriptional termination sequence (neo-tpA), has been targeted to the murine ROSA26 locus through homologous recombination [33,34]. Hence, expression of the alpha-synuclein transgene is driven by the ubiquitous, neuronal-selective murine ROSA26 promoter in discrete neuronal populations following Cre-mediated excision of the neo-tpA cassette (Fig. 1A). Following successful germ line transmission from chimeric mice for each line, the resulting heterozygous progeny (ROSA26-alphaSyn+/-, where + denotes the transgene) were intercrossed and analyzed by Southern blot to confirm correct targeting of the transgene at the ROSA26 locus (Fig. 1B). In general, heterozygous and homozygous ROSA26-alphaSyn mice are viable and fertile, exhibit normal survival, and manifest no gross behavioral or phenotypic abnormalities.
###end p 16
###begin p 17
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP </italic>
###xml 0 66 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Generation of Cre-<italic>loxP </italic>Conditional &#945;-Synuclein Transgenic Mice</bold>
###xml 212 216 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP</italic>
###xml 977 981 953 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EcoR</italic>
###xml 1140 1142 1112 1114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1293 1297 1265 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EcoR</italic>
###xml 1393 1396 1361 1364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1445 1449 1409 1413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1497 1504 1461 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">italics</italic>
###xml 1548 1551 1508 1511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1565 1569 1525 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold</italic>
###xml 1657 1663 1613 1619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/flox</sup>
###xml 2010 2014 1962 1966 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox</sup>
###xml 62 66 <span type="species:ncbi:10090">Mice</span>
###xml 139 154 <span type="species:ncbi:10090">transgenic mice</span>
###xml 156 161 <span type="species:ncbi:9606">Human</span>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
###xml 1104 1108 <span type="species:ncbi:10090">mice</span>
###xml 1404 1408 <span type="species:ncbi:10090">mice</span>
###xml 1559 1563 <span type="species:ncbi:10090">mice</span>
###xml 1735 1739 <span type="species:ncbi:10090">mice</span>
###xml 1799 1803 <span type="species:ncbi:10090">mice</span>
Generation of Cre-loxP Conditional alpha-Synuclein Transgenic Mice. (A) Gene targeting strategy for generating conditional ROSA26-alphaSyn transgenic mice. Human alpha-synuclein cDNAs were placed downstream of a loxP-flanked cassette containing a neomycin resistance gene (neo) and a triple transcriptional termination sequence (tpA). The entire neo-tpA-alphaSyn conditional transgene cassette is situated adjacent to the endogenous ROSA26 promoter. Following Cre-mediated excision of the neo-tpA cassette, the alpha-synuclein transgene is expressed from the adjacent ROSA26 promoter. ROSA26-alphaSyn mice were genotyped using the indicated PCR primers P1, P2 and P3. Primers P1/P3 produce a wild-type band of ~500 bp whereas primers P1/P2 produce a transgenic band of ~250 bp. Following Cre-mediated excision, primers P1/P3 can also amplify a ~1.5 kb band from the recombined transgenic allele. SA, splice acceptor; pA, polyadenylation sequence. (B) Southern blot analysis of EcoRV-digested tail genomic DNA derived from either wild-type (-/-), heterozygous (+/-) or homozygous (+/+) ROSA26-alphaSyn119 mice. Blots were hybridized with a [32P]-labeled DNA probe as indicated in (A). The probe detects the wild-type allele at ~11 kb and the transgenic allele at ~3.8 kb owing to an additional EcoRV site in the neo gene, as indicated. (C) Breeding strategy to produce floxed ROSA26-alphaSyn119+/+/TH-Cre mice and their non-floxed ROSA26-alphaSyn+/+ littermates at a frequency of 25% per genotype (italics). Notice that homozygous ROSA26-alphaSyn119+/+/TH-Cre mice (bold) were often produced with a germ line deletion (flox) of one allele (ROSA26-alphaSyn119+/flox/TH-Cre) at a ratio of 1:1 (+/+ to +/flox) following crossing to TH-Cre mice. (D) PCR genotyping strategy for ROSA26-alphaSyn119/TH-Cre mice using primers P1, P2 and P3 to distinguish the transgenic allele (Tg, ~250 bp, P1+P2), wild-type allele (WT, ~500 bp, P1+P3), or the transgenic allele following germline deletion of the neo-tpA cassette (Tgflox, ~1.5 kb, P1+P3).
###end p 17
###begin p 18
###xml 188 192 180 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 234 236 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 499 501 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 613 615 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 644 648 632 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 705 708 689 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 734 737 714 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 811 814 787 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 840 843 812 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 896 900 864 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 982 984 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1293 1299 1257 1263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/flox</sup>
###xml 1310 1315 1274 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C, D</xref>
###xml 1743 1746 1703 1706 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 1820 1823 1776 1779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1933 1938 1889 1894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C, D</xref>
###xml 136 151 <span type="species:ncbi:10090">transgenic mice</span>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
###xml 1343 1347 <span type="species:ncbi:10090">mice</span>
###xml 1532 1536 <span type="species:ncbi:10090">mice</span>
###xml 1660 1664 <span type="species:ncbi:10090">mice</span>
###xml 1758 1762 <span type="species:ncbi:10090">mice</span>
###xml 1831 1835 <span type="species:ncbi:10090">mice</span>
###xml 1875 1879 <span type="species:ncbi:10090">mice</span>
###xml 2008 2023 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2083 2088 <span type="species:ncbi:9606">human</span>
###xml 2125 2131 <span type="species:ncbi:10090">murine</span>
To induce conditional alpha-synuclein transgene expression, a two step breeding strategy was developed with either TH-Cre or nestin-Cre transgenic mice to derive homozygous ROSA26-alphaSyn+/+ mice with or without Cre expression (Fig. 1C). TH-Cre mice display Cre expression and activity restricted to central catecholaminergic neuronal populations within the substantia nigra pars compacta, ventral tegmental area, locus ceruleus, olfactory bulb, hypothalamic nuclei, and superior cervical ganglia [35]. Nestin-Cre mice show widespread expression of Cre activity in neuronal and glial cells throughout the brain [36]. Homozygous ROSA26-alphaSyn+/+ mice were first crossed with heterozygous ROSA26-alphaSyn+/-/TH-Cre or ROSA26-alphaSyn+/-/nestin-Cre mice in order to eventually produce homozygous ROSA26-alphaSyn+/+/TH-Cre or ROSA26-alphaSyn+/+/nestin-Cre mice and their non-floxed ROSA26-alphaSyn+/+ littermate controls at an expected frequency of 25% per genotype per litter (Fig. 1C). We notice however that passing the Cre transgene through the germline in this final breeding step results in germline excision of the neo-tpA cassette for one of the transgenic alleles in 100% of the progeny from crosses with nestin-Cre and ~50% of the progeny from crosses with TH-Cre i.e. ROSA26-alphaSyn+/flox/Cre (Fig. 1C, D). This produces homozygous mice with conditional transgene expression from one allele but widespread, unrestricted expression from the opposite allele. This was unexpected since expression of Cre transgenes in these mice is considered to be largely restricted to CNS tissues but they also appear to exhibit some activity in the germline in our mice. Thus, we were restricted to producing cohorts of heterozygous ROSA26-alphaSyn+/-/nestin-Cre mice but could successfully produce homozygous ROSA26-alphaSyn+/+/TH-Cre mice following screening and elimination of mice with germline excision of the neo-tpA cassette (Fig. 1C, D). Collectively, we have created an important resource of conditional transgenic mice capable of expressing A53T, E46K or C-terminally truncated human alpha-synuclein from the endogenous murine ROSA26 promoter in a Cre recombinase-dependent manner.
###end p 18
###begin title 19
###xml 28 33 <span type="species:ncbi:9606">Human</span>
Cre-Dependent Expression of Human A53T alpha-Synuclein and alphaSyn119
###end title 19
###begin p 20
###xml 570 573 546 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 650 652 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 815 818 783 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 908 910 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 351 356 <span type="species:ncbi:9606">Human</span>
###xml 581 585 <span type="species:ncbi:10090">mice</span>
###xml 639 643 <span type="species:ncbi:10090">mice</span>
###xml 689 694 <span type="species:ncbi:9606">human</span>
###xml 830 834 <span type="species:ncbi:10090">mice</span>
###xml 897 901 <span type="species:ncbi:10090">mice</span>
###xml 1021 1025 <span type="species:ncbi:10090">mice</span>
###xml 1052 1067 <span type="species:ncbi:10090">transgenic mice</span>
We next sought to verify that alpha-synuclein transgene expression in these mice can be induced in a Cre-dependent manner. Protein extracts were prepared from brain tissue of 10 month-old floxed ROSA26-alphaSyn/Cre mice and their non-floxed ROSA26-alphaSyn littermates followed by Western blot analysis with human-specific alpha-synuclein antibodies. Human alphaSyn119 expression is confirmed in brain regions with TH-positive neurons or nerve terminals including the olfactory bulb, striatum, cerebral cortex and ventral midbrain of floxed homozygous ROSA26-alphaSyn119+/+/TH-Cre mice that is completely absent from non-floxed littermate mice (Fig. 2A). Similarly, the expression of A53T human alpha-synuclein is confirmed in brain regions with nestin-positive neurons from floxed heterozygous ROSA26-alphaSyn-A53T+/-/nestin-Cre mice that is absent from the brains of their non-floxed littermate mice (Fig. 2A). Thus, both A53T alpha-synuclein and alphaSyn119 transgenes are expressed in a Cre-dependent manner in these mice. The E46K alpha-synuclein transgenic mice were not characterized further in this study.
###end p 20
###begin p 21
###xml 0 70 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cre-Dependent Human &#945;-Synuclein Expression in ROSA26-&#945;Syn Mice</bold>
###xml 226 229 209 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 270 274 249 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 536 539 503 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 586 590 549 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 934 937 876 879 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 964 967 902 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 994 997 928 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 1037 1041 967 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 14 19 <span type="species:ncbi:9606">Human</span>
###xml 66 70 <span type="species:ncbi:10090">Mice</span>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 315 320 <span type="species:ncbi:9606">human</span>
###xml 432 437 <span type="species:ncbi:9606">human</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 619 624 <span type="species:ncbi:9606">human</span>
###xml 713 718 <span type="species:ncbi:9606">human</span>
###xml 784 789 <span type="species:ncbi:9606">human</span>
###xml 1132 1137 <span type="species:ncbi:10090">mouse</span>
###xml 1163 1168 <span type="species:ncbi:9606">human</span>
###xml 1211 1216 <span type="species:ncbi:9606">human</span>
###xml 1273 1277 <span type="species:ncbi:10090">mice</span>
###xml 1282 1287 <span type="species:ncbi:10090">mouse</span>
###xml 1326 1341 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1421 1425 <span type="species:ncbi:10090">mice</span>
###xml 1451 1455 <span type="species:ncbi:10090">mice</span>
###xml 1562 1567 <span type="species:ncbi:9606">human</span>
Cre-Dependent Human alpha-Synuclein Expression in ROSA26-alphaSyn Mice. (A) Cre-dependent expression of alpha-synuclein variants. Protein extracts (50 mug) derived from distinct brain regions of 10 month-old ROSA26-alphaSyn119+/+/TH-Cre mice and their ROSA26-alphaSyn119+/+ littermate controls were probed with the human-specific alpha-synuclein antibody, Syn204, with actin and TH antibodies as controls. HEK-293T cells expressing human alphaSyn119 were used as a positive control. Equivalent proteins derived from ROSA26-alphaSyn-A53T+/-/nestin-Cre mice and their ROSA26-alphaSyn-A53T+/- littermates were probed with human-specific alpha-synuclein antibody, LB509, and actin antibody. HEK-293T cells expressing human alphaSyn-A53T were used as a positive control. (B) Comparison of human alphaSyn119 expression with endogenous alpha-synuclein. Proteins (50 mug) derived from distinct brain regions of 10 month-old ROSA26-alphaSyn119+/-/TH-Cre, ROSA26-alphaSyn119+/+/TH-Cre, ROSA26-alphaSyn119+/-/nestin-Cre and their ROSA26-alphaSyn119+/+ littermate controls were probed with alpha-synuclein antibody, Syn-1, to detect endogenous mouse (ms) alpha-synuclein and human alphaSyn119 expression. (C) Comparison of human A53T alpha-synuclein expression in ROSA26-alphaSyn-A53T mice and mouse prion promoter (mo.PrP) A53T-alphaSyn transgenic mice. Proteins extracted from ventral midbrain tissue of adult ROSA26-alphaSyn-A53T mice (50 mug) and mo.PrP-A53T mice (5 mug) were probed with LB509 antibody or actin antibody as a loading control. HEK-293T cells expressing human alphaSyn-A53T were used as a positive control.
###end p 21
###begin p 22
###xml 428 430 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 699 701 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 860 862 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 964 967 912 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 1014 1017 958 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1224 1226 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1363 1367 1299 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1440 1442 1372 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1466 1468 1398 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 837 841 <span type="species:ncbi:10090">mice</span>
###xml 979 983 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">mice</span>
###xml 1367 1371 <span type="species:ncbi:10090">mice</span>
###xml 1535 1540 <span type="species:ncbi:9606">human</span>
###xml 1626 1630 <span type="species:ncbi:10090">mice</span>
###xml 1667 1672 <span type="species:ncbi:9606">human</span>
To compare the expression level of human alphaSyn119 in the ROSA26-alphaSyn mice with endogenous alpha-synuclein, proteins extracted from various brain regions of 10 month-old ROSA26-alphaSyn119/Cre mice and their non-floxed littermates were analyzed by Western blotting with the alpha-synuclein antibody, Syn-1. alphaSyn119 is expressed at less than 10% of the levels of endogenous alpha-synuclein in these brain regions (Fig. 2B). This is perhaps not surprising since alphaSyn119 is expressed selectively in most TH-positive catecholaminergic neurons in these brain regions whereas endogenous alpha-synuclein is known to be expressed broadly within many neuronal populations throughout the brain [37]. It is possible to observe a doubling of alpha-Syn119 expression between heterozygous and homozygous floxed ROSA26-alphaSyn119/TH-Cre mice as expected (Fig. 2B). We could also confirm a broader distribution and higher levels of alphaSyn119 in ROSA26-alphaSyn119+/-/nestin-Cre mice compared to ROSA26-alphaSyn119+/+/TH-Cre mice reflecting the widespread distribution and greater number of nestin-positive neurons compared to the more restricted TH-positive catecholaminergic neuronal population in each brain region (Fig. 2B). A small proportion of truncated endogenous alpha-synuclein could also be detected in forebrain regions from control ROSA26-alphaSyn119+/+ mice that express the highest levels of endogenous alpha-synuclein (Fig. 2B), as noted previously [13]. It was not possible to directly compare the expression level of human A53T alpha-synuclein with endogenous alpha-synuclein in the ROSA26-alphaSyn-A53T/Cre mice since these proteins co-migrate and human alpha-synuclein expression does not appreciably influence the total level of alpha-synuclein detectable using the Syn-1 antibody (data not shown).
###end p 22
###begin p 23
###xml 212 214 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 215 217 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 590 592 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 799 812 779 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">heterozygous </italic>
###xml 832 835 808 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 899 910 875 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">homozygous </italic>
###xml 930 933 902 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 952 954 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 1072 1075 1036 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 1275 1277 1239 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
###xml 159 164 <span type="species:ncbi:9606">human</span>
###xml 199 204 <span type="species:ncbi:10090">mouse</span>
###xml 295 300 <span type="species:ncbi:10090">mouse</span>
###xml 428 433 <span type="species:ncbi:9606">human</span>
###xml 495 499 <span type="species:ncbi:10090">mice</span>
###xml 847 851 <span type="species:ncbi:10090">mice</span>
###xml 941 945 <span type="species:ncbi:10090">mice</span>
###xml 1020 1035 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1087 1091 <span type="species:ncbi:10090">mice</span>
###xml 1269 1273 <span type="species:ncbi:10090">mice</span>
###xml 1352 1356 <span type="species:ncbi:10090">mice</span>
###xml 1448 1453 <span type="species:ncbi:9606">human</span>
###xml 1543 1548 <span type="species:ncbi:9606">human</span>
###xml 1764 1768 <span type="species:ncbi:10090">mice</span>
###xml 1872 1876 <span type="species:ncbi:10090">mice</span>
###xml 1885 1890 <span type="species:ncbi:9606">human</span>
###xml 1906 1911 <span type="species:ncbi:9606">human</span>
###xml 2005 2011 <span type="species:ncbi:10090">murine</span>
###xml 2072 2087 <span type="species:ncbi:10090">transgenic mice</span>
Finally, we compared the expression level of A53T alpha-synuclein in our ROSA26-alphaSyn mice to a well-characterized mouse prion promoter (mo.PrP)-based A53T human alpha-synuclein neurodegenerative mouse model [19,38]. Despite the lack of obvious substantia nigra pathology in this mo.PrP-A53T mouse model, it is possible to detect more prominent alpha-synuclein expression in the ventral midbrain by Western blotting with the human-specific LB509 antibody compared to the ROSA26-alphaSyn-A53T mice with transgene expression directed to either TH-positive or nestin-positive neurons (Fig. 2C). This finding most likely relates to the relatively small contribution of TH-positive neurons to the total number of neurons within the ventral midbrain region which is highlighted by the observation that heterozygous ROSA26-alphaSyn-A53T+/-/nestin-Cre mice produced far greater transgene expression than homozygous ROSA26-alphaSyn-A53T+/+/TH-Cre mice (Fig. 2C). Greater alpha-synuclein expression observed in the mo.PrP-A53T transgenic mice compared to the ROSA26-alphaSyn-A53T+/-/nestin-Cre mice most likely relates to differences in the strength of the ROSA26 and mo.PrP promoters and/or transgene copy number, both of which are considered to be higher in the mo.PrP-A53T mice [19]. Due to the low level of transgene expression in the ROSA26-alphaSyn/Cre mice it was not possible to reliably demonstrate the selective neuronal distribution pattern of human alpha-synuclein above background by immunohistochemical methods with currently available human-specific alpha-synuclein antibodies or the Syn-1 antibody (data not shown). It was also not possible to observe the presence of alpha-synuclein pathological inclusions or aggregates in the substantia nigra of these mice up to 10 months of age (data not shown). Collectively, this data demonstrates that the ROSA26-alphaSyn mice express human alphaSyn119 or human A53T alpha-synuclein in a Cre-dependent manner but at lower levels than those of endogenous, murine alpha-synuclein or A53T alpha-synuclein expressed in mo.PrP transgenic mice.
###end p 23
###begin title 24
###xml 80 84 <span type="species:ncbi:10090">Mice</span>
Lack of Nigral Dopaminergic Neuronal Degeneration in alpha-Synuclein Transgenic Mice
###end title 24
###begin p 25
###xml 375 378 351 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 417 420 389 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 510 514 478 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 532 536 496 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 712 714 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 715 717 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 903 905 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 1082 1086 1034 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A&#8211;E</xref>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 433 448 <span type="species:ncbi:10090">transgenic mice</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">Mice</span>
###xml 1023 1028 <span type="species:ncbi:9606">human</span>
###xml 1177 1181 <span type="species:ncbi:10090">mice</span>
###xml 1327 1331 <span type="species:ncbi:10090">mice</span>
###xml 1481 1485 <span type="species:ncbi:10090">mice</span>
To determine whether the expression of human alphaSyn119 or A53T alpha-synuclein in the ROSA26-alphaSyn/Cre mice could contribute to the degeneration of nigrostriatal dopaminergic neurons with age, we generated suitably-sized cohorts of aged floxed and non-floxed mice. In particular, we generated alphaSyn119 or A53T alpha-synuclein mice crossed with TH-Cre (ROSA26-alphaSyn+/+/TH-Cre) or nestin-Cre (ROSA26-alphaSyn+/-/nestin-Cre) transgenic mice and their non-floxed age-matched littermates (ROSA26-alphaSyn+/- or ROSA26-alphaSyn+/+ mice). It is anticipated that TH-Cre and nestin-Cre mice would direct transgene expression in the vast majority of nigral dopaminergic neurons in the ROSA26-alphaSyn/Cre mice [35,36]. Mice were aged to 10-12 months and the numbers of TH-positive and Nissl-positive neurons in the substantia nigra pars compacta were counted using unbiased stereological methods (Fig. 3A). At this age, we fail to observe a significant loss of nigral dopaminergic neurons or Nissl-positive neurons due to human alphaSyn119 or A53T alpha-synuclein expression (Fig. 3A-E). In general, we do not observe alterations in the survival of the ROSA26-alphaSyn119/Cre mice up to 18 months of age. It is not possible to conclude whether or not the alphaSyn119 protein has pathophysiological properties since comparable mice expressing pathogenic A53T alpha-synuclein at identical levels in the same neurons also failed to influence dopaminergic neuronal viability in these mice.
###end p 25
###begin p 26
###xml 0 73 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Lack of Nigral Dopaminergic Neuronal Degeneration in ROSA26-&#945;Syn Mice</bold>
###xml 420 423 408 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 464 468 448 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 668 671 648 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 706 709 682 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 742 745 714 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 785 788 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 923 925 885 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1082 1084 1044 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 69 73 <span type="species:ncbi:10090">Mice</span>
###xml 202 206 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 800 804 <span type="species:ncbi:10090">mice</span>
###xml 931 935 <span type="species:ncbi:10090">mice</span>
Lack of Nigral Dopaminergic Neuronal Degeneration in ROSA26-alphaSyn Mice. Stereological analysis of TH-positive and Nissl-positive neurons in the substantia nigra pars compacta of male ROSA26-alphaSyn mice with or without Cre expression. (A) Example of immunohistochemical staining for TH with Nissl counterstain on coronal midbrain sections highlighting the substantia nigra region from 12 month-old ROSA26-alphaSyn119+/+/TH-Cre mice and their ROSA26-alphaSyn119+/+ littermate controls. (B-E) Stereological analysis revealing a normal number of TH-positive and Nissl-positive neurons in the substantia nigra pars compacta (SNpc) of 10-12 month-old ROSA26-alphaSyn119+/-/nestin-Cre (B), ROSA26-alphaSyn119+/+/TH-Cre (C), ROSA26-alphaSyn-A53T+/-/nestin-Cre (D) and ROSA26-alphaSyn-A53T+/+/TH-Cre (E) mice compared to their age-matched non-floxed ROSA26-alphaSyn littermates (Cre -). Data are expressed as the mean +/- SEM (n = 4-6 mice per genotype). There are no significant differences (p > 0.05) between genotypes following statistical analysis by unpaired, two-tailed Student's t test.
###end p 26
###begin title 27
Reduced Striatal Dopamine Induced by alphaSyn119 Expression in Catecholaminergic Neurons
###end title 27
###begin p 28
###xml 473 476 461 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 563 568 551 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A, B</xref>
###xml 612 615 596 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 880 884 856 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 925 930 901 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C, D</xref>
###xml 1081 1084 1053 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1114 1116 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 1776 1779 1732 1735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 2094 2101 2046 2053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 1092 1096 <span type="species:ncbi:10090">mice</span>
###xml 1213 1217 <span type="species:ncbi:10090">mice</span>
###xml 1375 1379 <span type="species:ncbi:10090">mice</span>
###xml 1475 1480 <span type="species:ncbi:9606">human</span>
###xml 1791 1795 <span type="species:ncbi:10090">mice</span>
###xml 1998 2013 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2037 2042 <span type="species:ncbi:9606">human</span>
To determine whether the expression of human alphaSyn119 in nigral dopaminergic neurons leads to nigrostriatal neuronal dysfunction, we monitored the levels of striatal dopamine and its metabolites in aged ROSA26-alphaSyn119/Cre mice and their non-floxed littermate control mice by HPLC. No differences in the levels of striatal dopamine or its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), are observed in heterozygous ROSA26-alphaSyn119+/-/nestin-Cre mice compared to their non-floxed littermates at 12-13 months of age (Fig. 4A, B). However, in homozygous ROSA26-alphaSyn119+/+/TH-Cre mice with an approximate doubling of alphaSyn119 expression in TH-positive dopaminergic neurons, we observe a significant marked reduction in the levels of striatal dopamine (~32%), DOPAC (~46%) and HVA (~33%) compared to their non-floxed ROSA26-alphaSyn119+/+ littermates at 10-11 months of age (Fig. 4C, D). This effect on the nigrostriatal dopaminergic system is specific since the levels of striatal 5-hydroxytryptamine (5-HT) in these ROSA26-alphaSyn119+/+/TH-Cre mice are normal (Fig. 4D). No further alterations in dopamine levels in other regions of the brain are observed in these mice, including the olfactory bulb, cerebral cortex and prefrontal cortex (data not shown). Furthermore, striatal dopamine turnover in the ROSA26-alphaSyn119/Cre mice is also normal (data not shown). Taken together, this data demonstrates that the expression of human alphaSyn119 in TH-positive catecholaminergic neurons leads to a reduction in striatal dopamine content in the absence of nigral dopaminergic neuronal loss. This effect would appear to be dependent on transgene dosage since the reduced expression of alphaSyn119 in heterozygous ROSA26-alphaSyn119+/-/nestin-Cre mice fails to induce deficits in striatal dopamine levels. Alternatively, this effect could potentially relate to mosaic expression of Cre recombinase in nigral dopaminergic neurons of TH-Cre and nestin-Cre transgenic mice. Our data suggest that human alphaSyn119 may be of pathophysiological relevance in vivo.
###end p 28
###begin p 29
###xml 0 113 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#945;Syn119 Expression in Catecholaminergic Neurons Leads to a Reduction of Striatal Dopamine and its Metabolites</bold>
###xml 403 406 391 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 459 463 443 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 548 551 528 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 600 604 576 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 749 751 723 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 781 783 755 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 945 947 919 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 789 793 <span type="species:ncbi:10090">mice</span>
alphaSyn119 Expression in Catecholaminergic Neurons Leads to a Reduction of Striatal Dopamine and its Metabolites. Analysis of striatal biogenic amines in ROSA26-alphaSyn119 mice by HPLC with electrochemical detection. The level of dopamine (A, C), or the dopamine metabolites, DOPAC and HVA, and 5-HT (B, D) were measured by HPLC in striatal tissue from (A, B) 12-13 month-old female ROSA26-alphaSyn119+/-/nestin-Cre mice (Cre +) and their ROSA26-alphaSyn119+/- littermate controls (Cre -) and from (C, D) 10-11 month-old female ROSA26-alphaSyn119+/+/TH-Cre mice (Cre +) and their ROSA26-alphaSyn119+/+ littermate controls (Cre -). The concentration of each biogenic amine is expressed as ng per mg of protein, and data represent the mean +/- SEM (n = 7-9 mice for nestin-Cre and n = 5-6 mice for TH-Cre). Significant differences between Cre- and Cre + genotypes were determined following statistical analysis by unpaired, two-tailed Student's t test (*p < 0.05, **p < 0.01).
###end p 29
###begin title 30
###xml 52 56 <span type="species:ncbi:10090">Mice</span>
Neurochemical Alterations in alphaSyn119 Transgenic Mice
###end title 30
###begin p 31
###xml 328 330 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 372 374 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 420 423 412 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 588 591 576 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 739 742 723 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 895 902 875 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
###xml 750 754 <span type="species:ncbi:10090">mice</span>
To further evaluate the potential pathophysiological effects of alphaSyn119 expression in the brain, the levels of the neurotransmitters norepinephrine (NE) and 5-HT were monitored in the olfactory bulb, cerebral cortex, prefrontal cortex, striatum and brainstem. A significant increase in the level of NE in the striatum (Fig. 5A) and 5-HT in the prefrontal cortex (Fig. 5B) is observed in homozygous ROSA26-alphaSyn119+/+/TH-Cre mice compared to their non-floxed littermates at 10-11 months of age. NE and 5-HT levels in these brain regions are normal in heterozygous ROSA26-alphaSyn119+/-/nestin-Cre mice at 12-13 months of age suggesting that the alterations in neurotransmitter levels are specific to the homozygous ROSA26-alphaSyn119+/+/TH-Cre mice (data not shown). Thus, alphaSyn119 expression in TH-positive catecholaminergic neurons induces additional subtle neurochemical alterations in vivo.
###end p 31
###begin p 32
###xml 0 87 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Neurochemical Alterations Caused by &#945;Syn119 Expression in Catecholaminergic Neurons</bold>
###xml 395 398 383 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 447 451 431 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 587 589 569 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 754 756 736 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
Neurochemical Alterations Caused by alphaSyn119 Expression in Catecholaminergic Neurons. Analysis of biogenic amines in discrete brain regions of ROSA26-alphaSyn119 mice by HPLC with electrochemical detection. The level of NE (A) and 5-HT (B) were measured by HPLC in olfactory bulb, cerebral cortex, prefrontal cortex, striatum and brainstem tissues of 10-11 month-old female ROSA26-alphaSyn119+/+/TH-Cre mice (Cre +) and their ROSA26-alphaSyn119+/+ littermate controls (Cre -). The concentration of NE and 5-HT is expressed as ng per mg of tissue, and data represent the mean +/- SEM (n = 5-7 mice per genotype). Significant differences between Cre - and Cre + genotypes were determined following statistical analysis by unpaired, two-tailed Student's t test (*p < 0.05).
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 64 79 <span type="species:ncbi:10090">transgenic mice</span>
###xml 91 96 <span type="species:ncbi:9606">human</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 903 908 <span type="species:ncbi:10090">mouse</span>
###xml 1259 1263 <span type="species:ncbi:10090">mice</span>
###xml 1303 1307 <span type="species:ncbi:10090">mice</span>
Here, we describe the development and evaluation of conditional transgenic mice expressing human alpha-synuclein pathological variants in dopaminergic neurons of the nigrostriatal pathway from the endogenous ROSA26 promoter. Our investigations have focused on the potential contribution of two pathologic variants, A53T mutant alpha-synuclein and C-terminally truncated alphaSyn119, to the normal integrity and function of nigral dopaminergic neurons with age. Our studies demonstrate that A53T alpha-synuclein and alphaSyn119 are expressed in a Cre recombinase-dependent manner in these ROSA26-alphaSyn mice. We show that neither A53T alpha-synuclein nor alphaSyn119 expression in mice aged for up to 12 months is sufficient to induce the degeneration of nigral dopaminergic neurons. However, we demonstrate that the expression of alphaSyn119 in nigral dopaminergic neurons for up to 12 months in this mouse model causes a marked reduction in the levels of striatal dopamine and its metabolites in addition to other subtle neurochemical alterations. Thus, at ages up to 12 months we observe nigrostriatal dopaminergic pathway dysfunction in the absence of frank neuronal loss. Further deficits in nigrostriatal dopaminergic function may be revealed in these mice with advanced age. The ROSA26-alphaSyn mice therefore represent a useful model of striatal dopamine depletion and could provide a potential presymptomatic model of PD perhaps representative of the earliest derangements in dopaminergic neuronal function observed prior to neuronal loss.
###end p 34
###begin p 35
###xml 122 129 114 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 565 567 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 568 570 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 795 797 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 798 800 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 886 895 842 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1096 1098 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1099 1101 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1102 1104 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1287 1295 1227 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1435 1437 1371 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1438 1440 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1497 1505 1429 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1560 1562 1492 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1563 1565 1495 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1690 1698 1618 1626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 513 518 <span type="species:ncbi:10090">mouse</span>
###xml 537 542 <span type="species:ncbi:9606">human</span>
###xml 778 793 <span type="species:ncbi:10090">transgenic mice</span>
Our data suggest that the C-terminally truncated alpha-synuclein variant, alphaSyn119, is of pathophysiological relevance in vivo. The expression of alphaSyn119 in nigral TH-positive dopaminergic neurons precipitates striatal dopamine loss without compromising dopaminergic neuronal viability. alphaSyn119, together with alphaSyn122 and alphaSyn123, are normally present in mammalian brain at low levels but are enriched as soluble and aggregated species in Lewy body-positive PD and DLB brains and in transgenic mouse brains expressing human A53T alpha-synuclein [13,29]. Furthermore, disease-associated mutations in alpha-synuclein promote the accumulation of alphaSyn119 and other truncation species compared to the wild-type protein in neural cell lines and alpha-synuclein transgenic mice [13,29]. Further supporting the pathogenicity of truncated alphaSyn119 and related species, in vitro studies demonstrate that C-terminally truncated alpha-synuclein variants fibrillize and aggregate more readily than the full-length protein and can seed the aggregation of full-length alpha-synuclein [13,29-31]. The mechanism through which alpha-synuclein C-terminal truncations arise is not known. alpha-Synuclein can be proteolytically processed at its C-terminus via a number of proteases in vitro, including cathepsin D and calpain I, but as yet none of these proteases have been shown to specifically generate the alphaSyn119 variant [39-42]. However, alphaSyn119 expression has been demonstrated in vivo and this variant accumulates in diseased brain tissue [13,29]. The normal and pathophysiological mechanism responsible for the generation of alphaSyn119 and similar truncation variants in vivo remains to be clarified.
###end p 35
###begin p 36
###xml 56 64 52 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 692 694 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 695 697 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 835 837 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1037 1045 1009 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1178 1180 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1351 1353 1311 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1578 1586 1530 1538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1685 1687 1633 1635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
###xml 1098 1113 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1123 1126 <span type="species:ncbi:10116">rat</span>
###xml 1195 1210 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1498 1503 <span type="species:ncbi:10090">mouse</span>
###xml 1719 1723 <span type="species:ncbi:10090">mice</span>
###xml 1871 1875 <span type="species:ncbi:10090">mice</span>
###xml 1896 1911 <span type="species:ncbi:10090">transgenic mice</span>
Our data in the ROSA26-alphaSyn mice provides the first in vivo demonstration of a pathophysiological effect of the disease-associated alphaSyn119 species on the nigrostriatal dopaminergic pathway. It is not yet clear how the expression of alphaSyn119 in dopaminergic neurons produces deficits in striatal dopamine levels in the absence of frank neuronal loss. alphaSyn119 could potentially induce the dysfunction or degeneration of striatal dopaminergic nerve terminals without compromising the integrity of the neuronal soma. At the cellular level, alphaSyn119 could impair pre-synaptic dopaminergic nerve terminals through the accumulation of submicroscopic toxic oligomers or aggregates [13,29], or could potentially sensitize nerve terminals to secondary insults such as oxidative and nitrosative stress that accumulate with age [43]. Future analyses of these mice will aim to clarify the mechanism through which alphaSyn119 could potentially act at nigrostriatal dopaminergic nerve terminals. The effects of alphaSyn119 expression in vivo are reminiscent to those of alphaSyn120 expressed in transgenic mice from the rat TH promoter on an alpha-synuclein null background [25]. alphaSyn120 transgenic mice exhibit a reduction in striatal dopamine and HVA levels that are first evident between 1-3 months but do not worsen up to 12 months of age [25]. Accompanying these alterations are late-onset motoric deficits and the formation of pathological alpha-synuclein inclusions. A caveat of this mouse model is that the alphaSyn120 truncated species has not yet been observed in vivo in brain tissue and may therefore represent a non-physiological truncated alpha-synuclein species [13]. Furthermore, the alphaSyn120 mice were generated on an alpha-synuclein null background which complicates the interpretation of their phenotype. Nevertheless, the ROSA26-alphaSyn119 mice and the alphaSyn120 transgenic mice suggest that C-terminal truncation of alpha-synuclein could represent a pathophysiological process during the development and/or propagation of PD that potentially contributes to the dysfunction of the nigrostriatal dopaminergic pathway.
###end p 36
###begin p 37
###xml 445 447 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 448 450 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 451 453 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1486 1488 1458 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1489 1491 1461 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 2125 2132 2077 2084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 2326 2328 2274 2276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 2941 2949 2869 2877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 395 401 <span type="species:ncbi:10090">murine</span>
###xml 666 670 <span type="species:ncbi:10090">mice</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
###xml 1544 1548 <span type="species:ncbi:10090">mice</span>
###xml 1687 1691 <span type="species:ncbi:10090">mice</span>
###xml 2180 2184 <span type="species:ncbi:10090">mice</span>
###xml 2670 2674 <span type="species:ncbi:10090">mice</span>
###xml 2803 2807 <span type="species:ncbi:10090">mice</span>
The ROSA26-alphaSyn mice offer an important resource for modeling various aspects of PD. These mice allow the expression of disease-associated alpha-synuclein variants selectively in nigrostriatal pathway dopaminergic neurons in order to evaluate their potentially pathogenic affects with age. Transgene expression in these mice is driven by the well-characterized neuronal-specific, endogenous murine ROSA26 promoter in a Cre-dependent manner [33,34,44]. This system permits the expression of alpha-synuclein variants in virtually any neuronal population in the brain depending upon the availability of suitable Cre driver lines. Conceivably, these ROSA26-alphaSyn mice could also be used to model other alpha-synucleinopathies, such as DLB, by directing transgene expression to neurons of the forebrain. A particularly attractive feature of these ROSA26-alphaSyn mice is that one can directly compare the effects of different pathological variants of the alpha-synuclein protein since variants are expressed at equivalent levels from the same stable promoter at identical copy number in the same neurons. This provides a clear advance over conventional transgenesis where individual founder lines can often produce marked differences in transgene expression levels and expression patterns due to the effects of genomic integration site, epigenetic modifications and transgene copy number. Of note, there are no known phenotypes associated with disruption of the ROSA26 genomic locus [33,44]. However, an obvious caveat of the ROSA26-alphaSyn mice is reduced transgene expression since only one to two transgene copies can be accommodated at the ROSA26 locus. Using the ROSA26-alphaSyn mice it is possible to co-express two pathological alpha-synuclein variants from opposite alleles at equivalent levels in the same neurons to investigate how they may interact to precipitate pathology or compromise neuronal viability. This feature allows one to examine, for example, whether alphaSyn119 expression can seed and accelerate the aggregation of the full-length alpha-synuclein variants, A53T or E46K, in dopaminergic neurons in vivo. Another useful feature of the ROSA26-alphaSyn mice is that they are ideally suited for investigating potential gene-environment interactions with dopamine neuron-specific toxins such as MPTP [45] since alpha-synuclein expression can be directed selectively to nigrostriatal pathway dopaminergic neurons using the TH-Cre driver line. In this scenario, one can directly compare the potential differential interaction of dopaminergic toxins with various pathogenic alpha-synuclein variants. Importantly, we have made these ROSA26-alphaSyn mice available as a unique resource to the PD research community by distribution through The Jackson Laboratory. The ROSA26-alphaSyn mice provide a useful and unique tool for evaluating the age-related effects of expressing alpha-synuclein pathogenic variants in neurons in vivo that will hopefully provide important insight into the molecular mechanisms underlying the pathogenesis of PD and DLB.
###end p 37
###begin title 38
Materials and methods
###end title 38
###begin title 39
###xml 66 70 <span type="species:ncbi:10090">Mice</span>
Generation and Breeding of Conditional alpha-Synuclein Transgenic Mice
###end title 39
###begin p 40
###xml 98 106 94 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">129/SvJ </italic>
###xml 146 148 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 202 205 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 211 214 203 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 294 298 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP</italic>
###xml 353 355 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 477 480 465 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pac</italic>
###xml 486 489 474 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Asc</italic>
###xml 498 500 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 562 565 546 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 664 672 648 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">129/SvJ </italic>
###xml 819 821 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 822 824 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 866 875 850 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C57BL/6J </italic>
###xml 954 963 938 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C57BL/6J </italic>
###xml 1535 1537 1519 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1538 1540 1522 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 658 663 <span type="species:ncbi:10090">mouse</span>
###xml 875 880 <span type="species:ncbi:10090">mouse</span>
###xml 912 916 <span type="species:ncbi:10090">mice</span>
###xml 963 967 <span type="species:ncbi:10090">mice</span>
###xml 1024 1029 <span type="species:ncbi:10090">mouse</span>
###xml 1236 1241 <span type="species:ncbi:10090">Mouse</span>
###xml 1267 1271 <span type="species:ncbi:10090">mice</span>
###xml 1586 1590 <span type="species:ncbi:10090">mice</span>
###xml 1592 1596 <span type="species:ncbi:10090">mice</span>
Human alpha-synuclein variants (E46K, A53T or 1-119) were targeted to the ROSA26 genomic locus in 129/SvJ embryonic stem (ES) cells as described [34]. Briefly, alpha-synuclein cDNAs were subcloned into XhoI and NotI sites of acceptor plasmid pBigT thereby placing the transgene downstream of a loxP-flanked neo-tpA transcriptional termination cassette [34]. The entire neo-tpA-alpha-synuclein conditional transgene was excised and inserted into targeting plasmid pROSA26PA via PacI and AscI sites [34]. The final pROSA26PA-alphaSyn construct was linearized with KpnI, gel purified with GELase reagent (Epicenter, Madison, WI) and used for electroporation of mouse 129/SvJ ES cells. Following G418 selection, at least six correctly targeted ES cell clones were identified by PCR and Southern blot analysis as described [33,34], and two clones were microinjected into C57BL/6J mouse blastocysts to derive chimeric mice. Four to six chimeras were bred with C57BL/6J mice for each targeting construct with at least one chimeric mouse producing germline transmission of the correctly targeted allele to F1 progeny. ES cell selection, blastocyst microinjection and chimera breeding was conducted by the University of Cincinnati Gene-Targeted Mouse Service. F1 heterozygous mice were routinely identified by PCR of tail genomic DNA with primers: P1, 5'-aaagtcgctctgagttgttat-3'; P2, 5'-gcgaagagtttgtcctcaacc-3'; P3, 5'-ggagcgggagaaatggatatg-3'; producing a ~500 bp product from the WT allele and a ~250 bp product from the transgenic allele [33,34]. Following intercrossing of F1 heterozygous mice, mice were further analyzed by Southern blot to verify correct targeting of the transgene at the ROSA26 locus.
###end p 40
###begin p 41
###xml 40 48 36 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">129/SvJ </italic>
###xml 52 61 48 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C57BL/6J </italic>
###xml 93 102 89 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C57BL/6J </italic>
###xml 183 185 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 203 205 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 244 253 240 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C57BL/6J </italic>
###xml 441 445 433 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 520 523 508 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 588 592 572 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 668 676 652 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">129/SvJ </italic>
###xml 680 689 664 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C57BL/6J </italic>
###xml 767 779 747 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- or, +/+ </sup>
###xml 1015 1017 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1072 1074 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1240 1288 1216 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Guide for the Care and Use of Laboratory Animals</italic>
###xml 1407 1417 1383 1393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum</italic>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 207 222 <span type="species:ncbi:10090">transgenic mice</span>
###xml 276 291 <span type="species:ncbi:10090">transgenic mice</span>
###xml 397 401 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 1055 1070 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1151 1155 <span type="species:ncbi:10090">mice</span>
###xml 1290 1294 <span type="species:ncbi:10090">Mice</span>
###xml 1439 1443 <span type="species:ncbi:10090">mice</span>
ROSA26-alphaSyn mice were maintained as 129/SvJ and C57BL/6J hybrids through backcrossing to C57BL/6J mice for 1-2 generations and then intercrossing of heterozygous progeny. TH-Cre [35] and nestin-Cre [36] transgenic mice were maintained on a C57BL/6J background. Nestin-Cre transgenic mice (stock number 003771) were obtained from The Jackson Laboratory (Bar Harbor, ME). To generate cohorts of mice for aging, heterozygous ROSA26-alphaSyn+/- mice were crossed with each hemizygous Cre line, and the F1 ROSA26-alphaSyn+/-/Cre progeny were further crossed with homozygous ROSA26-alphaSyn+/+ mice to produce F2 mice. The F2 mice produced from these crosses on a mixed 129/SvJ and C57BL/6J hybrid background were used throughout this study. Age-matched ROSA26-alphaSyn+/- or, +/+ littermates without Cre were used as controls. Cre transgenes were genotyped by an established PCR protocol with the primers 5'-AAATGTTGCTGGATAGTTTTTACTGC-3' and 5'-GGAAGGTGTCCAATTTACTGACCGTA-3' to produce a 300 bp transgenic fragment [35]. Adult hemizygous PrP-A53T-alphaSyn transgenic mice [19] were kindly provided by Dr. Michael K. Lee (Johns Hopkins University). All mice were housed and treated in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice were maintained in a pathogen-free facility and exposed to a 12 h light/dark cycle with food and water provided ad libitum. The ROSA26-alphaSyn mice are available from The Jackson Laboratory (Bar Harbor, ME; ); JAX stock number, 008883 (ROAS26-Syn-A53T), 008886 (ROSA26-Syn-E46K) and 008889 (ROSA26-Syn119).
###end p 41
###begin title 42
Western blot analysis
###end title 42
###begin p 43
###xml 373 375 373 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 1209 1211 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1382 1384 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
###xml 749 754 <span type="species:ncbi:9606">human</span>
###xml 764 769 <span type="species:ncbi:10090">mouse</span>
###xml 859 864 <span type="species:ncbi:10090">mouse</span>
###xml 1129 1134 <span type="species:ncbi:9606">human</span>
###xml 1376 1380 <span type="species:ncbi:10090">mice</span>
###xml 1415 1419 <span type="species:ncbi:10090">mice</span>
Brain regions, including the olfactory bulb, cerebral cortex, striatum, ventral midbrain, brainstem and cerebellum, from 10 month-old mice were dissected from fresh brains, homogenized in ice-cold RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 1x Complete Mini protease inhibitor cocktail [Roche]), and then centrifuged at 20,000 x g for 15 min at 4degreesC. The RIPA-soluble supernatant fraction was collected, quantified using BCA reagent (Pierce, Rockford, IL) with BSA standards, and stored at -80degreesC. Proteins (100 mug) were resolved by electrophoresis on 15% SDS-PAGE gels and transferred to nitrocellulose membranes (0.2 mum; Biorad). To detect alpha-synuclein expression, blots were probed with human-specific mouse monoclonal antibodies, Syn204 (Cell Signaling Technology) and LB509 (Zymed), or with the mouse monoclonal Syn-1 antibody (BD Bioscience). Antibodies to tyrosine hydroxylase (Novus Biologicals) and actin (Sigma) were used to control for regional dissection and protein loading, respectively. Lysates derived from HEK-293T cells transiently expressing untagged human alpha-synuclein (A53T or Syn119; pcDNA3.1 expression vector [Invitrogen] [19]) served as positive controls for alpha-synuclein antibodies. To compare A53T alpha-synuclein expression in ventral midbrain tissue from adult mo.PrP-A53T-alphaSyn mice [19] and ROSA26-alphaSyn-A53T/Cre mice, proteins were prepared as described above and analyzed by Western blotting with LB509 antibody.
###end p 43
###begin title 44
Immunohistochemistry and Stereological Cell Counting
###end title 44
###begin p 45
###xml 1223 1225 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1226 1228 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 233 237 <span type="species:ncbi:9925">goat</span>
###xml 308 314 <span type="species:ncbi:9986">rabbit</span>
###xml 436 440 <span type="species:ncbi:9925">goat</span>
###xml 533 537 <span type="species:ncbi:9925">goat</span>
###xml 600 604 <span type="species:ncbi:9925">goat</span>
###xml 610 616 <span type="species:ncbi:9986">rabbit</span>
###xml 714 718 <span type="species:ncbi:9925">goat</span>
Perfusion-fixed coronal midbrain sections (40-mum) were cut on a sliding microtome (Microm, Kalamazoo, MI) and collected free-floating in PBS. Sections were permeabilized and blocked in PBS containing 0.4% Triton X-100 and 4% normal goat serum at room temperature for 30 min. Sections then were incubated in rabbit polyclonal anti-TH antibody (1:1000; Novus Biologicals, Littleton, CO) in PBS containing 0.2% Triton X-100 and 2% normal goat serum overnight at 4degreesC and washed with PBS containing 0.2% Triton X-100 and 1% normal goat serum. Next, sections were incubated for 1 hr in biotinylated goat anti-rabbit antibody (1:1000; Jackson ImmunoResearch, West Grove, PA) in PBS with 0.2% Triton X-100 and 1.5% goat serum, washed, and visualized by incubation in biotin-streptavidin-HRP complex (ABC; Vector Laboratories, Burlingame, CA), followed by incubation with 3,3'-diaminobenzidine per the manufacturer's instructions (Sigma). Sections were mounted on glass slides and allowed to air dry overnight before being counterstained with Nissl, dehydrated with ethanol, and cover-slipped for visualization. To evaluate dopaminergic neuronal loss, unbiased stereological methodology was employed as described previously [46,47] to count TH-positive and Nissl-positive neurons in the left and right pars compacta region of every fourth section throughout the entire midbrain region. This method was carried out by using a computer-assisted image analysis system, consisting of an Axiophot 2 photomicroscope (Carl Zeiss Vision, Hallbergmoos, Germany) equipped with a computer-controlled motorized stage (Ludl Electronics, Hawthorne, NY), a Hitachi HV C20 video camera, and interfaced with a Stereo Investigator system (MicroBrightField, Williston, VT, USA) with optical fractionator probe.
###end p 45
###begin title 46
Measurement of Biogenic Amines by HPLC
###end title 46
###begin p 47
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 855 857 839 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 1014 1015 991 992 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1017 1018 994 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
HPLC with electrochemical detection was used to measure the concentration of the biogenic amines, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid (5-HIAA) and norepinephrine (NE) in discrete brain regions, as previously described [48]. Female ROSA26-alphaSyn/Cre mice and age-matched ROSA26-alphaSyn littermate controls were sacrificed by decapitation, brains were quickly removed and frozen on dry ice, and stored at -80degreesC. Striata, prefrontal cortex, cerebral cortex, olfactory bulb and brainstem were dissected from frozen tissue and samples were weighed and sonicated in 0.2 ml of 0.1 M perchloric acid (at 100 mul/mg tissue) containing 0.01% EDTA and 25 mug/ml 3,4-dihydroxybenzylamine (DHBA, Sigma) as an internal standard. Following centrifugation at 15,000 x g for 10 min at 4degreesC, 20 mul of supernatant was injected onto a C-18 80 x 4.6 mm column (ESA, Inc Chelmsford, MA). The mobile phase consisted of 0.1 M LiH2PO4, 0.85 mM 1-octanesulfonic acid and 10% (v/v) methanol. The flow rate was kept at 1 ml/min. Biogenic amines and their metabolites were detected by a 2-channel Coulochem II electrochemical detector (ESA, Inc. Chelmsford, MA) with the working electrode kept at 0.7 V. Data were collected and processed using external standards for respective amines on a EZChrome Elite Client Workstation (ESA, Inc. Chelmsford, MA). Concentrations of biogenic amines are expressed as ng per mg protein. The protein concentrations of tissue homogenates were measured using BCA reagent (Pierce, Rockford, IL).
###end p 47
###begin title 48
Statistical Analysis
###end title 48
###begin p 49
###xml 274 276 272 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 327 329 325 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Throughout the experiments investigators were blinded to genotype of the mice. Data represent mean +/- S.E.M. from groups of animals for each genotype. Statistical analysis for stereology and HPLC assessments between genotypes were assessed by unpaired, two-tailed Students t test. Differences were considered significant when p < 0.05. All statistical analyses were performed using GraphPad InStat-version 3 and Prism software (San Diego, CA).
###end p 49
###begin title 50
Abbreviations
###end title 50
###begin p 51
DLB: dementia with Lewy bodies; DOPAC: 3,4-dihydroxyphenylacetic acid; 5-HT: 5-hydroxytryptamine; HVA: homovanillic acid; NE: norepinephrine; neo: neomycin; PD: Parkinson's disease; TH: tyrosine hydroxylase; tpA: transcriptional termination sequence.
###end p 51
###begin title 52
Competing interests
###end title 52
###begin p 53
The authors declare that they have no competing interests.
###end p 53
###begin title 54
Authors' contributions
###end title 54
###begin p 55
TMD and DJM designed the research, JPD, MY, RB, RSM, LY and BT conducted the experiments, TMD and DJM contributed new research tools, MDH, BT, MFB, VLD, TMD and DJM supervised the experiments and provided reagent and infrastructure support, JPD, MY, BT, TMD and DJM analyzed the data, DJM prepared the manuscript, BT, MFB, VLD and TMD critically reviewed the manuscript. All authors read and approved the final manuscript.
###end p 55
###begin title 56
Acknowledgements
###end title 56
###begin p 57
###xml 141 156 <span type="species:ncbi:10090">transgenic mice</span>
We are grateful to Dr. Michael K. Lee (Johns Hopkins University) for helpful discussions on this work and for providing mo.PrP-A53T-alphaSyn transgenic mice. This work was supported by grants from the Michael J. Fox Foundation for Parkinson's Research (DJM, TMD, MFB), Department of Defense (MFB), Parkinson's Disease Foundation (MFB), and NIH, NINDS, R21 NS057795 (DJM, TMD), RO1 NS060885 (BT) and P50 NS038377 (TMD). TMD is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases at Johns Hopkins University.
###end p 57
###begin article-title 58
Parkinson's disease. Second of two parts
###end article-title 58
###begin article-title 59
Parkinson's disease. First of two parts
###end article-title 59
###begin article-title 60
Staging of brain pathology related to sporadic Parkinson's disease
###end article-title 60
###begin article-title 61
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies
###end article-title 61
###begin article-title 62
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease [letter]
###end article-title 62
###begin article-title 63
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease [see comments]
###end article-title 63
###begin article-title 64
alpha-Synuclein locus triplication causes Parkinson's disease
###end article-title 64
###begin article-title 65
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia
###end article-title 65
###begin article-title 66
Mendelian forms of Parkinson's disease
###end article-title 66
###begin article-title 67
Molecular mechanisms of alpha-synuclein neurodegeneration
###end article-title 67
###begin article-title 68
alpha-Synuclein is phosphorylated in synucleinopathy lesions
###end article-title 68
###begin article-title 69
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions
###end article-title 69
###begin article-title 70
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations
###end article-title 70
###begin article-title 71
Value of genetic models in understanding the cause and mechanisms of Parkinson's disease
###end article-title 71
###begin article-title 72
###xml 33 38 <span type="species:ncbi:9606">human</span>
alpha-Synucleinopathy models and human neuropathology: similarities and differences
###end article-title 72
###begin article-title 73
In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?
###end article-title 73
###begin article-title 74
###xml 81 86 <span type="species:ncbi:9606">human</span>
Neuronal a-synucleinopathy with sever movement disorder in micer expressing A53T human a-synuclein
###end article-title 74
###begin article-title 75
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 96 111 <span type="species:ncbi:10090">transgenic mice</span>
Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice
###end article-title 75
###begin article-title 76
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 161 176 <span type="species:ncbi:10090">transgenic mice</span>
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice
###end article-title 76
###begin article-title 77
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders
###end article-title 77
###begin article-title 78
###xml 77 92 <span type="species:ncbi:10090">transgenic mice</span>
###xml 129 134 <span type="species:ncbi:9606">human</span>
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies
###end article-title 78
###begin article-title 79
###xml 46 61 <span type="species:ncbi:10090">transgenic mice</span>
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters
###end article-title 79
###begin article-title 80
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 34 39 <span type="species:ncbi:9606">human</span>
Neuropathology in mice expressing human alpha-synuclein
###end article-title 80
###begin article-title 81
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 87 102 <span type="species:ncbi:10090">transgenic mice</span>
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice
###end article-title 81
###begin article-title 82
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 125 130 <span type="species:ncbi:9606">human</span>
Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders
###end article-title 82
###begin article-title 83
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice
###end article-title 83
###begin article-title 84
###xml 28 43 <span type="species:ncbi:10090">transgenic mice</span>
###xml 55 60 <span type="species:ncbi:9606">human</span>
Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter
###end article-title 84
###begin article-title 85
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 67 82 <span type="species:ncbi:10090">transgenic mice</span>
Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice
###end article-title 85
###begin article-title 86
A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease
###end article-title 86
###begin article-title 87
Synthetic filaments assembled from C-terminally truncated alpha-synuclein
###end article-title 87
###begin article-title 88
Role of alpha-synuclein carboxy-terminus on fibril formation in vitro
###end article-title 88
###begin article-title 89
###xml 134 138 <span type="species:ncbi:10090">mice</span>
Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice
###end article-title 89
###begin article-title 90
Generalized lacZ expression with the ROSA26 Cre reporter strain
###end article-title 90
###begin article-title 91
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
###end article-title 91
###begin article-title 92
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
Bcl-x is required for proper development of the mouse substantia nigra
###end article-title 92
###begin article-title 93
Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety
###end article-title 93
###begin article-title 94
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons
###end article-title 94
###begin article-title 95
###xml 36 51 <span type="species:ncbi:10090">transgenic mice</span>
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death
###end article-title 95
###begin article-title 96
Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro
###end article-title 96
###begin article-title 97
Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein
###end article-title 97
###begin article-title 98
Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation
###end article-title 98
###begin article-title 99
Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species
###end article-title 99
###begin article-title 100
Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation
###end article-title 100
###begin article-title 101
###xml 135 140 <span type="species:ncbi:10090">mouse</span>
Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells
###end article-title 101
###begin article-title 102
MPTP as a mitochondrial neurotoxic model of Parkinson's disease
###end article-title 102
###begin article-title 103
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism
###end article-title 103
###begin article-title 104
New stereological methods for counting neurons
###end article-title 104
###begin article-title 105
###xml 99 103 <span type="species:ncbi:10090">mice</span>
MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity
###end article-title 105

